Preparation and application of heteroaryl derivative
By developing heteroaryl derivatives with significant inhibitory activity, the problem of limited therapeutic options for LRRK2 kinase and EGFR mutant kinase in the prior art is solved, and an effective treatment plan for central nervous system diseases and cancer is provided.
Patent Information
- Application Number
- CN202310589148.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art treatment options for LRRK2 kinases or abnormal LRRK2 mutant kinases and EGFR mutant kinases are limited, and effective selective inhibitors are lacking in the treatment of neurodegenerative diseases and other diseases associated with these enzymes.
A heteroaryl derivative has been developed with significant LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase inhibitory activity for the preparation of related drugs for the prevention and treatment of central nervous system diseases, cancer and immune diseases.
This heteroaryl derivative showed significant antizyme activity in the experiment, able to effectively inhibit LRRK2 and EGFR kinases, providing new therapeutic options, especially with potential applications for the treatment of LRRK2-related diseases and cancers.
Smart Images

Figure CN119019454A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of organic compounds, and in particular to the preparation and use of a heteroaryl derivative. Background Art
[0002] LRRK2 (leucine-rich repeat kinase-2) protein belongs to the leucine-rich repeat kinase family and consists of a 2527 amino acid sequence with high interspecies similarity. The LRRK2 protein is characterized by showing GTPase and serine-threonine kinase activity in a single protein. The expressed LRRK2 protein is observed in a variety of organs and tissues including the brain, and it is present in the cytoplasm or cell membrane and mitochondrial outer membrane at the cellular level. In addition, the LRRK2 protein has five functionally important domains, and its regulatory cell function is inferred through protein interactions and enzymatic actions as well as through the autoregulatory effects of autophosphorylation. In particular, it is known that the chaperone mechanism, cytoskeleton arrangement, protein translation mechanism, synaptic vesicle endocytosis, mitogen-activated protein kinase-type cascade and ubiquitin / autophagy protein degradation pathway are regulated by the LRRK2 protein.
[0003] It is reported that LRRK2 protein is associated with the progression of mild cognitive impairment associated with Alzheimer's disease, levodopa-induced dyskinesia, and central nervous system diseases associated with neural precursor differentiation. In addition, it is reported that the S2019S mutation of the LRRK2 protein increases the incidence of non-skin cancers, such as acute myeloid leukemia, renal cancer, breast cancer, lung cancer, prostate cancer, etc. Specifically, the G2019S mutation of the LRRK2 protein increases the catalytic activity of the LRRK2 kinase domain. In addition, it is reported that LRRK2 protein is also associated with amyotrophic lateral sclerosis, rheumatoid arthritis, and ankylosing spondylitis. High expression of LRRK2 is highly correlated with advanced clinical features and poor survival rates in patients with ovarian cancer. The inhibition or depletion of LRRK2 increases the sensitivity of breast cancer drugs to ovarian cancer cells and enhances the efficacy.
[0004] EGFR is a receptor for epithelial growth factor (EGF) cell proliferation and signal transduction. EGFR belongs to the ErbB receptor family, which includes EGFR (ErbB-1), HER2 / c-neu (ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4). EGFR is also known as HER1 and ErbB1. EGFR is widely distributed on the cell surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, etc. The EGFR signaling pathway plays an important role in physiological processes such as cell growth, proliferation and differentiation. EGFR is divided into three regions: the extracellular ligand binding region, the transmembrane region and the intracellular kinase region. When EGFR is bound by the corresponding ligand, it will induce it to form homo- or hetero-dimers, thereby activating the intracellular tyrosine kinase pathway and causing it to phosphorylate itself, thereby guiding downstream phosphorylation, including MAPK, Akt and JNK pathways, and inducing cell proliferation. EGFR mutant kinase inhibitors block the binding of endogenous ATP to the intracellular kinase region, thereby inhibiting receptor phosphorylation and the activation of its downstream signal transduction molecules, thereby blocking the proliferation of tumor cells.
[0005] Although there have been many studies on LRRK2 kinase or abnormal LRRK2 mutant kinase inhibitors and EGFR mutant kinase inhibitors, there are currently limited treatment options, and there is still a need to develop effective and selective LRRK2 kinase or abnormal LRRK2 mutant kinase inhibitors and EGFR mutant kinase inhibitors for the treatment and / or prevention of neurodegenerative diseases or other diseases related to LRRK2 or / and EGFR. Summary of the invention
[0006] The present application provides a heteroaryl derivative and provides applications of the compound.
[0007] The technical solution of the present invention is as follows:
[0008] 1. Heteroaryl derivatives
[0009] A heteroaryl derivative, or a pharmaceutically acceptable salt, ester or prodrug thereof, has the following general structural formula I:
[0010]
[0011] in:
[0012] X and Y are independently selected from halogen or hydrogen, or together with the nitrogen-containing six-membered ring to which they are connected, form a nitrogen-containing five-membered ring;
[0013] Preferably, Y is selected from Cl, X is selected from H, or the nitrogen-containing six-membered ring to which they are connected together forms
[0014] R1 is a 5-6 membered aromatic group or a heteroaromatic group containing N and S, the aromatic ring and the heteroaromatic group are substituted by 0-2 substituents, the substituents are C1-3 alkyl groups or alkyl groups substituted by cyano groups; or two substituents can be connected to form a ring, the ring is a 5-7 membered cycloalkyl group, a lactam cycloalkyl group or a heterocycloalkyl group or heteroaromatic group containing N and O, the heterocycloalkyl group or heteroaromatic group is substituted by 0-3 substituents, the substituents are C1-3 alkyl groups, keto groups, trifluoroacetyl groups, hydroxyacetyl groups, alkylamino groups, heterocycloalkanoyl groups.
[0015] Preferably, R1 is
[0016] One of them.
[0017] Preferably, the compound of formula I is one of the following:
[0018] Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0019] (2-(2-(1-methyl-1H-pyrazol-4-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;
[0020] (2-(2-(1-methyl-1H-pyrazol-3-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;
[0021] (2-(2-((1H-indazol-6-yl)amino)-7H-purin-6-amino)phenyl)dimethylphosphine oxide;
[0022] (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;
[0023] 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone
[0024] 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one
[0025] (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;
[0026] 6-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;
[0027] (2-((2-(1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;
[0028] 7-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;
[0029] (2-((2-(1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;
[0030] 2-(4-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile;
[0031] (2-((6-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0032] (2-((6-(((5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridin-2-yl)amino)-1H-pyrazol[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0033] (2-((6-((6-propylamino)-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0034] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)yl)-2,2,2-trifluoroethanone;
[0035] (2-((6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0036] 1-(3-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;
[0037] (2-((2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0038] (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0039] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;
[0040] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-2,2,2-trifluoroethanone;
[0041] (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0042] 2-(4-((4-)((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile;
[0043] 6-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;
[0044] (2-(((1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide;
[0045] 7-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;
[0046] (2-(((1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide;
[0047] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;
[0048] 2-(2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0049] (2-((5-chloro-2-((6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0050] 1-(2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone;
[0051] (2-(5-chloro-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)pyrimidin-4-yl)amine)phenyldimethylphosphine oxide;
[0052] (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0053] 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;
[0054] (2-((5-chloro-2-((6-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;
[0055] 2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-4H-thiazolo[4,5-d]azepin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone;
[0056] 2-(4-(5-Chloro-4-(2-dimethylphosphonophenyl)aminopyrimidin-2-ylamino)-3-methylpyrazole-2-methylpropionitrile.
[0057] 2. Application of Heteroaryl Derivatives
[0058] The heteroaryl derivatives of the general formula I of the present invention show significant enzyme inhibitory activity in LRRK2 kinase or abnormal LRRK2 mutant kinase and / or EGFR mutant kinase inhibitory activity experiments;
[0059] Therefore, the present application provides the use of heteroaryl derivatives in the preparation of drugs related to the inhibition of LRRK2 kinase or abnormal LRRK2 mutant kinase and / or EGFR mutant kinase.
[0060] An inhibitor of LRRK2 kinase or abnormal LRRK2 mutant kinase comprises the heteroaryl derivative of the present invention or its enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient.
[0061] An EGFR mutant kinase inhibitor comprises the heteroaryl derivative of the present invention or its enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient.
[0062] A dual inhibitor of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase comprises the heteroaryl derivative of the present invention or its enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient.
[0063] The use of the heteroaryl derivatives of general formula I described in the present application or their pharmaceutically acceptable salts or excipients, or pharmaceutical compositions, or dual inhibitors of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase in the preparation of drugs for preventing and / or treating central nervous system diseases, cancers and immune diseases.
[0064] Among them, the central nervous system (CNS) diseases include Alzheimer's disease, L-dopa-induced dyskinesia, Parkinson's disease, ischemic stroke, traumatic brain injury or spinal cord injury; the cancers include kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myeloid leukemia, multiple myeloma, brain cancer, etc.; the immune diseases include leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis or ankylosing spondylitis.
[0065] A pharmaceutical composition comprises the heteroaryl derivative of general formula I or its enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient.
[0066] The pharmaceutical composition of the present invention can also be used in combination with other drugs, wherein the other drugs are drugs for treating breast cancer.
[0067] Pharmaceutically acceptable salts of the compounds of general formula I include conventional salts formed with pharmaceutically acceptable inorganic or organic acids, or inorganic or organic bases. Examples of suitable acid addition salts include salts formed with hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, perchloric acid, fumaric acid, acetic acid, propionic acid, succinic acid, glycolic acid, formic acid, lactic acid, maleic acid, tartaric acid, citric acid, pamoic acid, malonic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, hydroxybenzoic acid, hydroiodic acid, malic acid, tannic acid, etc. Examples of suitable base addition salts include salts formed with sodium, lithium, potassium, magnesium, aluminum, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucose and procaine, etc.
[0068] When referring to the compounds of the present invention herein, it includes the compounds of formula I and pharmaceutically acceptable salts or solvates thereof.
[0069] The compound of formula I of the present invention can be combined with conventional pharmaceutical carriers or excipients to form a pharmaceutical composition.
[0070] The pharmaceutical composition can be administered orally or parenterally. The pharmaceutical composition of the present invention can be prepared into various dosage forms according to conventional methods in the art, including but not limited to tablets, capsules, solutions, suspensions, granules or injections, and administered orally or parenterally.
[0071] New structural modifications and in-depth studies on the compounds of the present invention are helpful for developing new LRRK2 kinase or abnormal LRRK2 mutant kinase inhibitors, EGFR mutant kinase inhibitors, or dual inhibitors of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase, and are helpful for developing new drugs with good application prospects and practical value. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 p-Rab10 Western Blot for compound 23 in LRRK2 R1441G MEFS;
[0073] Figure 2p-Rab10 Western Blot for compound 25 in LRRK2 R1441G MEFS;
[0074] Figure 3 p-Rab10 Western Blot for compound 32 in LRRK2 R1441G MEFS;
[0075] Figure 4 For brain tissue immunoblotting experiment (Western Blot);
[0076] Figure 5 This is a plasma immunoblot experiment (Western Blot). DETAILED DESCRIPTION
[0077] The present invention is further described in detail in conjunction with the following specific examples and drawings, and the protection content of the present invention includes but is not limited to the following examples. The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention has no special restrictions.
[0078] Example 1: Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0079]
[0080] Step 1: To n-butanol (50 mL) were added a suspension of 2,6-dichloro-7H-purine (2.00 g, 10.6 mmol), (2-aminophenyl)dimethylphosphine oxide (1.79 g, 10.6 mmol) and TFA (60 mg, 0.53 mmol) in sequence, and the suspension was stirred at 120 ° C. for 48 h to obtain a reaction solution; the reaction solution was cooled to room temperature, and the solvent was removed under reduced pressure. The residue was separated and purified by silica gel column purification (dichloromethane / methanol = 50 / 1-20 / 1) to obtain the target compound 1c (yield 38.2%, 1.30 g, off-white solid). 1 HNMR (400MHz, DMSO): δ13.35 (s, 1H), 11.94 (s, 1H), 8.68 (d, J = 4.4Hz, 1H), 8.26 (s, 1H) ), 7.62 (dt, J = 15.6, 8.0 Hz, 2H), 7.19 ( t, J = 7.2 Hz, 1H), 1.80 ( dd, J = 13.6, 5.6 Hz, 6H).
[0081] Step 2: 1c (0.40 g, 1.24 mmol), 6-amino-1,4-benzodioxetine (188 mg, 1.24 mmol) and TFA (14 mg, 0.12 mmol) were added to n-butanol (10 mL) in sequence to obtain a suspension, which was stirred at 120° C. for 24 h to obtain a reaction solution. The reaction solution was cooled to room temperature, the solvent was removed under reduced pressure, and the residue was separated and purified by silica gel column purification (dichloromethane / methanol=30 / 1-10 / 1) to obtain the target compound (yield 36.3%, 197 mg, gray solid). 1 H NMR (400MHz, DMSO): δ12.61(s,1H),11.41(s,1H),8.97(dd,J=8.4,4.4Hz,1H),8.89(s,1H),7.87(s,1H),7.57 -7.52(m,3H),7.18-7.01(m,2H),6.75(d,J=8.8Hz,1H),4.21(dd,J=12.4,5.1Hz,4H),1.79(d,J=13.6Hz,6H); LC-MS(ESI)m / z: 437.1[M+H] + .
[0082] Example 2: Preparation of (2-(2-(1-methyl-1H-pyrazol-4-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide
[0083]
[0084] Refer to the synthesis steps of Example 1 to obtain Example 2. 1 HNMR (400MHz, DMSO-d6): δ12.56(s,1H),11.26(s,1H),8.92(s,1H),8.79(s,1H),7.88(s,1H),7.82(s,1H),7.67-7 .49(m,2H),7.47(s,1H),7.14(t,J=7.2Hz,1H),3.78(s,3H),1.80(s,3H),1.76(s,3H); LC-MS(ESI)m / z:383.0[M+H] + .
[0085] Example 3: Preparation of (2-(2-(1-methyl-1H-pyrazol-3-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide
[0086]
[0087] Referring to the synthesis steps of Example 1, Example 3 was obtained. 1H NMR(400MHz,DMSO-d6)δ12.53(s,1H),11.44(s,1H),9.19(s,1H),9.14–9.07(m,1H),7.86(s,1H),7.60-7.50(m,2 H),7.46(t,J=8.0Hz,1H),7.09(t,J=7.2Hz,1H),6.55(d,J=2.0Hz,1H),3.75(s,3H),1.80(s,3H),1.77(s,3H).31P NMR (162MHz, DMSO-d6) δ44.47 (s); LC-MS (ESI) m / z: 383.1[M+H]+.
[0088] Example 4: Preparation of (2-(2-((1H-indazol-6-yl)amino)-7H-purine-6-amino)phenyl)dimethylphosphine oxide
[0089]
[0090] Example 4 was obtained by referring to the synthesis steps of Example 1. 1 H NMR(400MHz,DMSO-d6)δ12.76(s,1H),11.48(s,1H),9.25(s,1H),9.01(s,1H),8.11(s,1H),7.93( d,J=7.2Hz,2H),7.66-7.44(m,4H),7.39(d,J=8.4Hz,1H),7.12(s,1H),1.82(s,3H),1.78(s,3H); 31 P NMR(162MHz,DMSO-d6)δ44.53(s); LC-MS(ESI)m / z:419.25[M+H] + .
[0091] Example 5: Preparation of (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide
[0092]
[0093] Step 1: 1-(2-amino-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethane-1-one 5a (200 mg, 0.80 mmol) and (2-((2-chloro-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide 5b (360 mg, 0.80 mmol) were dissolved in 1,4-dioxane (5.0 mL) at room temperature. Pd2(dba)3 (148 mg, 0.16 mmol), cesium carbonate (510 mg, 1.6 mmol) and xantphos (204.74 mg, 2.13 mmol) were added to the reaction mixture under argon protection, and the temperature was raised to 110°C and stirred for 16 hours. After the reaction mixture was cooled to room temperature, it was filtered and concentrated under reduced pressure to obtain a brown solid. The residue was separated and purified by silica gel column chromatography (DCM / MeOH=1 / 0-10 / 1) to obtain the target compound 5c (yield 69.28%, 313 mg, yellow solid). LC-MS (ESI) m / z: 565.1 [M+H] + .
[0094] Step 2: At room temperature, 5c (50 mg, 0.088 mmol) was dissolved in DCM (3 mL), TFA (1 mL) was added, and the reaction was stirred at room temperature for 16 h. The residue was concentrated under reduced pressure and purified by Prep-HPLC to give the title compound (15.32 mg, yield 40.07%, white solid). 1 H NMR (400MHz, DMSO-d6) δ12.80(s,1H),11.63(s,1H),9.69(s,1H),9.10(s,3H),8.23(d,J=8.4Hz,1H),8.00(s,1H),7.61(d,J=8.8H z,1H),7.58-7.49(m,1H),7.14(t,J=7.2Hz,1H),4.27(s,2H),3.56-3.49(m,2H),3.01(t,J=6.0Hz,2H),1.81(s,3H),1.78(s,3H). 31 P NMR (162MHz, DMSO-d6) δ44.72 (s); LC-MS (ESI) m / z: 435.2[M+H] + .
[0095] Example 6: Preparation of 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone
[0096]
[0097] Step 1: At room temperature, 5c (80 mg, 0.14 mmol) (MC22-424-048) was dissolved in dichloromethane (5.0 mL). DIEPA (0.5 mL, 0.28 mmol), DMAP (1.7 mg, 0.014 mmol) and TFAA (88.3 mg, 0.42 mmol) were added to the reaction mixture at zero degrees Celsius, and the mixture was stirred at 25°C for 2 hours. After the reaction was completed, water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (DCM / MeOH=1 / 0–10 / 1) to obtain the target compound 6a (yield 64.93%, 68 mg, yellow solid). LC-MS (ESI) m / z: 661.0 [M+H] + .
[0098] Step 2: At room temperature, 6a (50 mg, 0.088 mmol) was dissolved in DCM (3 mL), TFA (1 mL) was added, and the reaction was stirred at room temperature for 16 h. The residue was concentrated under reduced pressure and purified by Prep-HPLC to give the target compound (10.23 mg, yield 19.3%, white solid). 1 H NMR(400MHz,DMSO-d6)δ11.69(s,1H),8.94(s,1H),8.10(s,1H),7.96(s,1H),7.84(s,1H),7.72–7.45(m,2H),7.1 8(t,J=6.6Hz,1H),4.78(d,J=9.4Hz,2H),3.94(d,J=5.6Hz,4H),2.96(d,J=14.8Hz,2H),1.82(s,3H),1.79(s,3H); 19 F NMR(377MHz, DMSO-d6)δ-68.40(s),-74.23(s); 31 P NMR (162MHz, DMSO-d6) δ44.49; LC-MS (ESI) m / z: 531.0[M+H] + .
[0099] Example 7: Preparation of 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one
[0100]
[0101] Step 1: 5c (70 mg, 0.12 mmol) and 2-hydroxyacetic acid (74.5 mg, 0.98 mmol) were dissolved in DMF (5.0 mL) at room temperature, DIEPA (1.3 mL, 0.6 mmol) and HATU (221.3 mg, 0.42 mmol) were added to the reaction mixture and stirred at 25 ° C for 1 hour. After the reaction was completed, water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (DCM / MeOH=1 / 0-10 / 1) to obtain the target compound 7a (yield 85.11%, 90 mg, white solid). LC-MS (ESI) m / z: 623.1 [M+H] + .
[0102] Step 2: 7a (90 mg, 0.14 mmol) (MC22-424-056) was dissolved in DCM (3 mL) at room temperature, TFA (1 mL) was added, and the reaction was stirred at room temperature for 16 hours, concentrated under reduced pressure, and the residue was separated and purified by Prep-HPLC to obtain the target compound 7 (18.89 mg, yield 27.39%, white solid); 1 H NMR (400MHz, DMSO-d6) δ12.82(s,1H),11.62(s,1H),9.56(s,1H),9.11(s,1H),8.13(s,1H),7.99(s,1H),7.74–7.43(m,4H),7.13(t,J=7.2Hz ,1H),4.58(d,J=28Hz,2H),4.20(d,J=12..4Hz,2H),3.82(s,1H),3.70(t,J=5.6Hz,1H),2.89(s,1H),2.81(s,1H),1.81(s,3H),1.78(s,3H); 31 P NMR (162MHz, DMSO-d6) δ44.69 (s); LC-MS (ESI) m / z: 493.0 [M+H] + .
[0103] Example 8: Preparation of dimethyl (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)phosphine oxide
[0104]
[0105] Step 1: At room temperature, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine (49.01 mg, 0.29 mmol) and 5b (90 mg, 0.19 mmol) were dissolved in 1,4-dioxane (10.0 mL). Brettphos G3Pd (18.12 mg, 0.02 mmol) and sodium tert-butoxide (39.4 mg, 0.40 mmol) were added to the reaction mixture under argon protection, and the mixture was stirred at 110°C for 3 hours. After the reaction mixture was cooled to room temperature, it was filtered and concentrated under reduced pressure to obtain a brown solid. The residue was separated and purified by silica gel column chromatography (DCM / MeOH=1 / 0–15 / 1) to obtain the target compound 8b (yield 52.24%, 180 mg, red solid). LC-MS (ESI) m / z: 585.1 [M+H] + .
[0106] Step 2: At room temperature, 8b (180 mg, 0.3 mmol) was dissolved in DCM (3.00 mL), TFA (1.00 mL) was slowly added dropwise to the solution, and the reaction was stirred at room temperature for 3 hours. After the reaction was completed, it was concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to obtain the target compound (45.38 mg, yield 33.32%, yellow solid). 1 H NMR(400MHz,DMSO–d6)δ12.93(s,1H),11.60(s,1H),11.44(s,1H),9.01(s,1H),8.03(s,1H),7.67-7.57(m,1H) ,7.53(t,J=7.7Hz,1H),7.18(t,J=7.2Hz,1H),4.36(s,2H),3.52(s,2H),2.93(s,5H),1.80(s,3H),1.77(s,3H); 31 P NMR (162MHz, DMSO-d6) δ43.88 (s); LC-MS (ESI) m / z: 455.0[M+H] + .
[0107] Example 9: Preparation of 6-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one
[0108]
[0109] At room temperature, TsOH·H2O (20 mg, 10 wt%) was added to 6-amino-3,4-dihydroquinolin-2(1H)-one (0.20 g, 1.23 mmol) and 1c (0.40 g, 1.23 mmol) in n-BuOH (40 mL) solvent. After argon replacement three times, the mixture was heated to 120°C and stirred for 48 h. The reaction was complete as monitored by TLC. The reaction solution was cooled to room temperature and concentrated under reduced pressure to obtain a brown oil, which was purified by silica gel column chromatography (DCM / MeOH=1 / 0-30 / 1) to obtain the target compound 9 (yield 34.4%, 190 mg, gray solid). ; 1 H NMR (400MHz, DMSO) δ12.59(s,1H),11.39(s,1H),9.91(s,1H),9.02-8.76(m,2H),7.89(s,1H),7.66-7.36(m,4 H),7.18-7.05(m,1H),6.76(d,J=8.4Hz,1H),2.82(t,J=7.6Hz,2H),2.48-2.37(m,2H),1.79(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ44.24 (s); LC-MS (ESI) m / z: 448.2[M+H]+.
[0110] Example 10: Preparation of (2-((2-(1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide
[0111]
[0112] At room temperature, BH3·Me2S (0.55 mL, 2 Min THF, 1.12 mmol) was added to a solution of compound 9 (50 mg, 0.11 mmol) in THF (5 mL), and the mixture was heated to 50°C and stirred for 4 h. TLC monitored the reaction to be complete. The reaction solution was cooled to room temperature, methanol (10 mL) was slowly added dropwise, and heated to reflux for 0.5 h. The mixture was cooled to room temperature, and dilute hydrochloric acid (6 M, 10 mL) was added, and heated to reflux for 0.5 h. The reaction solution was concentrated under reduced pressure to obtain a brown solid. Purification by silica gel column chromatography gave the target compound (yield 48.8%, 23.65 mg, brown solid). 1H NMR (400MHz, DMSO) δ12.44(s,1H),11.35(s,1H),8.96(s,1H),8.48(s,1H),7.80(s,1H),7.54(dd,J=14.4,7.4Hz,1H),7.43(t,J=7.6Hz,1H),7.10 (dd,J=21.6,14.1Hz,3H),6.38(d,J=8.8Hz,1H),5.30(s,1H),3.39(d,J= 5.2Hz,2H),3.21-3.10(m,2H),2.69-2.58(m,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ44.29 (s); LC-MS (ESI) m / z: 434.2[M+H]+.
[0113] Example 11: Preparation of 7-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one
[0114]
[0115] Example 11 was obtained by referring to the synthesis steps of Example 9.
[0116] 1 H NMR (400MHz, DMSO) δ12.61(s,1H),11.44(s,1H),10.02(s,1H),9.06(s,1H),8.98(dd,J=7.6,4.1Hz,1H),7.90( s,1H),7.62-7.36(m,3H),7.16-7.00(m,3H),2.82(t,J=7.6Hz,2H),2.48-2.39(m,2H),1.79(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ44.46 (s); LC-MS (ESI) m / z: 448.2[M+H]+.
[0117] Example 12: Preparation of (2-((2-(1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide
[0118]
[0119] Example 12 was obtained by referring to the synthesis steps of Example 10. 1H NMR (400MHz, DMSO) δ12.53(s,1H),11.39(s,1H),9.02(s,1H),8.67(s,1H),7.85(s,1H),7.61-7.44(m,2H),7.10(t,J=7.2Hz,1H),6.91(d,J =6.4Hz,1H),6.72(d,J=7.6Hz,2H),5.41(s,1H),4.43(s,1H),3.39(s,2H),3.21-3.12(m,2H),2.62(t,J=6.0Hz,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ44.36 (s); LC-MS (ESI) m / z: 434.2[M+H]+.
[0120] Example 13: Preparation of 2-(4-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0121]
[0122] Example 12 was obtained by referring to the synthesis steps of Example 8. 1 H NMR(400MHz,DMSO–d6)δ12.55(s,1H),11.41(s,1H),8.80(s,1H),8.32(s,1H),7.98 -7.95(m,2H),7.74–7.35(m,2H),7.09(t,J=7.2Hz,1H),2.16(s,3H),1.93(s,6H),1.79(d,J=13.4Hz,6H). 31 P NMR (162MHz, DMSO) δ44.34 (s); LC-MS (ESI) m / z: 450.2 [M+H] + .
[0123] Example 14: Preparation of (2-((6-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0124]
[0125] Step 1: DHP (1.07 g, 12.7 mmol) and TsOH·H2O (100 mg, 0.53 mmol) were added to a THF (40 mL) solvent of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine 14a (2.00 g, 10.6 mmol) at room temperature, and the mixture was heated to 40°C and stirred for 6 h. The reaction was completed by TLC monitoring. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was purified and separated by silica gel column chromatography (PE / EA=1 / 0-10 / 1) to obtain the target compound 14b (yield 72.7%, 2.10 g, white solid). 1 H NMR(400MHz, CDCl3)δ8.19(s,1H),6.00(dd,J=10.4,2.5Hz,1H),4.12(dd,J=10.4,3.1Hz,1H),3.80(td,J=11.6,2.4Hz, 1H), 2.65-2.46 (m, 1H), 2.14 (dd, J=9.6, 3.6Hz, 1H), 1.95 (dd, J=12.4, 2.8Hz, 1H), 1.83-1.71 (m, 2H), 1.70-1.61 (m, 1H).
[0126] Step 2: At room temperature, (2-aminophenyl) dimethylphosphine oxide (0.31 g, 1.83 mmol) and DIEA (0.71 g, 5.49 mmol) were added to a solution of 14b (0.50 g, 1.83 mmol) in NMP (10 mL), replaced with argon three times, heated to 80 ° C and stirred for 4 h. TLC monitored the reaction to be complete. The reaction solution was cooled to room temperature, poured into ice water (50 mL), extracted with EA (50 mL × 3), the organic phase was washed with saturated NaCl aqueous solution (100 mL × 3), dried over anhydrous sodium sulfate, and concentrated to obtain a brown oil, which was purified and separated by silica gel column chromatography (PE / EA = 1 / 0-1 / 2) to obtain the target compound (yield 28.3%, 210 mg, white solid). LC-MS (ESI) m / z: 406.0 [M+H] +.
[0127] Step 3: Synthesize the target compound 14d by referring to Step 1 of Example 5 (yield 41.3%, 53 mg, brown solid). LC-MS (ESI) m / z: 521.1 [M+H]+.
[0128] Step 4: Under argon protection, HCl / MeOH (1 mL, 4 M) was added to a solution of 14d (85 mg, 0.15 mmol) in methanol (2 mL) and stirred at room temperature for 3 h. TLC monitored the reaction to be complete. The reaction solution was concentrated under reduced pressure to obtain a brown oil, which was purified by Prep-TLC (DCM / MeOH / NH3·H2O=10 / 1 / 0.001) to obtain the target compound 14 (yield 42.5%, 30.3 mg, brown solid). 1 H NMR (400MHz, DMSO) δ13.06(s,1H),12.05(s,1H),9.15(s,1H),9.02(s,1H),7.74(s,1H),7.62(dd,J=
[0129] 31P NMR (162MHz, DMSO) δ47.95 (s); LC-MS (ESI) m / z: 437.1[M+H]+.
[0130] Example 15: Preparation of (2-((6-(((5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridin-2-yl)amino)-1H-pyrazol[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0131]
[0132] Example 15 was obtained by referring to the synthesis steps of Example 14, wherein in step 3, Cs2CO3 was replaced by KCO3, and the other steps remained unchanged. 1 H NMR(400MHz,MeOD)δ8.50(s,1H),7.97(dd,J=12.8,8.0Hz,1H),7.82(t,J=6.4Hz,2H),7.70(dd,J=7.2,5.6Hz,1H),4 .23(d,J=58.4Hz,2H),3.78(s,1H),3.50(s,1H),2.98(s,2H),1.80(d,J=13.6Hz,6H); LC-MS(ESI)m / z:455.2[M+H]+.
[0133] Example 16: (2-((6-((6-propylamino)-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0134]
[0135] Example 16 was obtained by referring to the synthesis steps of Example 15. 1 HNMR(400MHz,DMSO)δ13.31(s,1H),12.16(s,1H),11.28(s,1H),9.11(s,1H),7.81(s,1H),7.64(dd,J=1 3.6,8.0Hz,1H),7.54(t,J=7.6Hz,1H),7.19(t,J=7.2Hz,1H),4.10(d,J=4.8Hz,1H),3.17(d,J=4.4Hz,1 H),2.91(d,J=11.6Hz,2H),2.65(d,J=16.8Hz,1H),2.58(t,J=7.2Hz,2H),2.39(dd,J=16.0,8.4Hz,1H), 1.99(s,1H),1.81(t,J=20.4Hz,6H),1.59(d,J=7.2Hz,1H),1.51-1.34(m,2H),0.89(t,J=7.2Hz,3H); 31P NMR (162MHz, DMSO) δ48.00-47.19 (m); LC-MS (ESI) m / z: 497.3[M+H]+.
[0136] Example 17: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)yl)-2,2,2-trifluoroethanone
[0137]
[0138] Step 1: Compound 17a was obtained by referring to Step 1 of Example 8 (yield 20.95%, 103 mg, yellow solid). LC-MS (ESI) m / z: 615.0 [M+H] + .
[0139] Step 2: 17a (50 mg, 0.08 mmol) was dissolved in MeOH (1.00 mL) at room temperature, 4N HCl / MeOH (2.00 mL) was slowly added dropwise to the solution, and the reaction was stirred at room temperature for 16 h. The residue was concentrated under reduced pressure and purified by Prep-HPLC to give the title compound (3.84 mg, yield 9.05%, white solid). 1H NMR(400MHz,MeOD–d4)δ8.71(s,1H),8.50–8.14(m,1H),7.92(s,1H),7.82–7.66(m,2H),7.4 3(s,1H),7.31(s,1H),4.07(s,2H),3.35(s,2H),3.26–3.20(m,2H),1.92(d,J=13.6Hz,6H). 19 F NMR(377MHz,MeOD–d4)δ-70.92(d,J=39.0Hz),-77.17(s); 31 P NMR(162MHz,MeOD–d4)δ67.56–61.58(m); LC-MS(ESI)m / z: 531.2[M+H] + .
[0140] Example 18: Preparation of (2-((6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0141]
[0142] Step 1: Using 5a and 14c as raw materials, refer to the synthesis step 1 of Example 8 to obtain the intermediate product (yield 30.13%, 125 mg, yellow solid). LC-MS (ESI) m / z: 519.0 [M+H] +.
[0143] Step 2: Refer to Step 2 of Example 17 to synthesize the target product. 1 H NMR(400MHz,MeOD–d4)δ8.67(s,1H),8.30(s,1H),7.87–7.63(m,3H),7.62–7.33(m ,2H),4.42(s,2H),3.67(t,J=6.2Hz,2H),3.33(s,4H),1.92(d,J=13.6Hz,6H); 31P NMR (162MHz, MeOD–d4) δ48.36–43.37 (m); LC-MS (ESI) m / z: 435.3[M+H]+.
[0144] Example 19: Preparation of 1-(3-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one
[0145]
[0146] Using the product of step 1 of example 18 as a raw material, Example 19 was synthesized by referring to step 1 of example 7 and step 4 of example 14. 1 H NMR (400MHz, DMSO) δ14.30(s,1H),13.24(s,1H),10.80(s,1H),10.26(s,1H),9.49(s,1H),9.33(d,J=8.4Hz,1H),8.85(s,1H),8.73-8.51( m,2H),8.21(t,J=7.2Hz,1H),5.64(d,J=27.6Hz,2H),5.26(d,J=11.6Hz,2H),4.75(s,2H),3.91(d,J=32.0Hz,2H),2.91(d,J=13.6Hz,6H); 31 P NMR (162MHz, MeOD–d4) δ 49.35 (s); LC-MS (ESI) m / z: 493.1 [M+H] + .
[0147] Example 20: Preparation of (2-((2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0148]
[0149] Step 1: 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (2 g, 10.64 mmol) and DIEA (2.744 g, 10.638 mmol) were dissolved in DMF (40.0 mL) at room temperature. SEM-Cl (2.744 g, 21.28 mmol) was added to the reaction mixture at zero degrees Celsius and stirred at room temperature for 2 hours. After the reaction was completed, water (50 mL) was added and extracted with ethyl acetate (50 mL x 2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (PE / EA=1 / 0–2 / 1) to obtain the target compound (yield 84.45%, 2.86 g, transparent oil). LC-MS (ESI) m / z: 318.0 [M+H] +.
[0150] Step 2: At room temperature, 2,4-dichloro-7-(2-trimethylsilylethoxy)methyl-7H-pyrrolo[2,3-d]pyrimidine (2.0 g, 6.28 mmol) (MC22-424-096) and (2-aminophenyl)dimethylphosphine oxide were dissolved in DMF (40 mL), potassium tert-butoxide (1.408 g, 12.56 mmol) was added, and the mixture was stirred at zero degrees Celsius for 2 hours. After the reaction was completed, water (80 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (100 mL×2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (PE / EA=1 / 0–2 / 1) to obtain the target compound (yield 84.45%, 2.86 g, gray solid). LC-MS (ESI) m / z: 451.0 [M+H]+.
[0151] Step 3: Refer to the synthesis step 1 of Example 8 to obtain 20d. LC-MS (ESI) m / z: 566.0 [M+H] + .
[0152] Step 4: 20d (148 mg) was dissolved in DCM (3.00 mL), TFA (1.00 mL) was slowly added dropwise to the solution, and the reaction was stirred at room temperature for 3 hours. After the reaction was completed, it was concentrated under reduced pressure. The residue was dissolved in MeOH (2.50 mL), NH3H2O (2.50 mL) was slowly added dropwise to the solution, and the reaction was stirred at room temperature for 6 hours. After the reaction was completed, it was concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to obtain the target compound (31.24 mg, yield 24.13%, white solid). 1 H NMR(400MHz,MeOD–d4)δ8.88–8.75(m,1H),7.68-7.39(m,2H),7.32(d,J=2.4Hz,1H),7.17-7.07(m,1H),6.98–6.91 (m,1H),6.86(d,J=3.6Hz,1H),6.71(d,J=8.8Hz,1H),6.40(d,J=3.6Hz,1H),4.24-4.18(m,4H),1.88-1.83(m,6H); 31 P NMR(162MHz,MeOD–d4)δ49.22(s); LC-MS(ESI)m / z: 436.05[M+H] + .
[0153] Example 21: Preparation of (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7Hpyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0154]
[0155] Step 1: Refer to the synthetic step 1 of Example 8 to obtain a product with a protected group. LC-MS (ESI) m / z: 584.1 [M+H] + .
[0156] Step 2: Refer to the synthesis step 4 of Example 20 to obtain the target product. 1 H NMR(400MHz,DMSO–d6)δ11.76(s,1H),11.51(s,1H),11.03(s,1H),9.33 -9.10(m,1H),7.63–7.53(m,1H),7.50(t,J=7.8Hz,1H),7.10(t,J=7.2Hz,1H),7.05–6.99(m,1H),6.4 5–6.39(m,1H),3.58(s,2H),2.78(d,J=5.4Hz,2H),2.67(s,2H),2.44(s,3H),1.83(d,J=13.6Hz,6H); 31 P NMR(162MHz,DMSO–d6)δ47.07(s); LC-MS(ESI)m / z: 454.0[M+H] + .
[0157] Example 22: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one
[0158]
[0159] Example 22 was synthesized by referring to step 1 of Example 7 and step 4 of Example 20. 1 H NMR (400MHz, DMSO–d6) δ11.93-11.90(m,2H),9.03(s,1H),7.84(d,J=26.8Hz,2H),7.70-7.50(m,2H),7.26-7.11(m, 2H),6.49(s,1H),4.62(d,J=21.6Hz,2H),4.22(d,J=16.4Hz,2H),3.74(s,2H),3.00(s,2H),1.85(d,J=13.6Hz,6H); 31 P NMR(162MHz,DMSO–d6)δ47.15(s); LC-MS(ESI)m / z: 492.3[M+H] + .
[0160] Example 23: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-2,2,2-trifluoroethanone
[0161]
[0162] At room temperature, Example 24 was dissolved in DCM (5.00 mL), TEA (68.8 mg, 0.68 mmol) and TFAA (214 mg, 1.02 mmol) were added to the solution, and the reaction was stirred at room temperature for 1 hour. After the reaction was completed, it was concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to obtain the target compound (6.23 mg, yield 3.46%, white solid). 1 H NMR(400MHz,DMSO–d6)δ12.02(s,1H),11.88(s,1H),9.03(s,1H),7.89(s,2H),7.71–7.52(m,2H),7.18(s,2H ), 6.50 (s, 1H), 4.79 (d, J = 9.6Hz, 2H), 3.96 (d, J = 6.0Hz, 2H), 3.03 (d, J = 14.0Hz, 2H), 1.85 (d, J = 13.6Hz, 6H); 19 F NMR(377MHz, DMSO–d6)δ-68.45(d,J=30.1Hz),-74.01(s); 31 P NMR(162MHz, DMSO–d6)δ47.09(s); LC-MS(ESI)m / z: 530.1[M+H] + .
[0163] Example 24: Preparation of (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0164]
[0165] The target product 24 was obtained by deprotection with reference to step 1 of Example 8 and step 4 of Example 20. 1H NMR (400MHz, DMSO-d6) δ11.96(s,1H),11.77(s,1H),10.24(s,1H),9.21(s,1H),9.11(s,1H),8.04(s,1H),7.72(d,J=8.3Hz,1H),7.62(dd,J =14.2,7.6Hz,1H),7.55(t,J=7.8Hz,1H),7.13(s,1H),6.47(s,1H),4.29(s,2H),3.53(s,2H),3.07(d,J=5.9Hz,2H),1.84(d,J=13.6Hz,6H); 31 P NMR(162MHz, DMSO–d6)δ47.15(s); LC-MS(ESI)m / z: 434.2[M+H] + .
[0166] Example 25: Preparation of 2-(4-((4-)((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0167]
[0168] Step 1: 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile and 20c were used as raw materials to obtain a protected product according to the synthetic step 1 of reference example 8. LC-MS (ESI) m / z: 579.3 [M+H] + .
[0169] Step 2: Deprotection is performed according to step 4 of the synthesis of reference 20 to obtain the target product. 1 H NMR (400MHz, CDCl3) δ11.36-11.17(m,1H),9.27-8.97(m,1H),8.78-8.62(m,1H),8.20-8.02(m,1H),7.61-7.50(m,1H),7.30-7.26(m ,1H),7.25-7.22(m,1H),7.15-7.04(m,1H),6.60-6.42(m,1H),6.41-6.31(m,1H),2.29(s,3H),1.98(s,6H),1.88(d,J=13.2Hz,6H); 31 P NMR(162MHz, CDCl3)δ48.08-47.28(m); LC-MS(ESI)m / z:449.1[M+H] + .
[0170] Example 26: Preparation of 6-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(H)-one
[0171]
[0172] Example 26 was obtained by referring to the synthesis steps of Example 9. 1 H NMR (400MHz, DMSO) δ11.96(s,1H),11.77(s,1H),10.24(s,1H),9.21(s,1H),9.11(s,1H),8.04(s,1H),7.72(d,J=8.3Hz,1H),7.62(dd,J=14.2,7. 6Hz,1H),7.55(t,J=7.8Hz,1H),7.13(s,1H),6.47(s,1H),6.76(d,J=8.4 Hz,1H),2.82(t,J=7.6Hz,2H),2.48-2.37(m,2H),1.80(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.12 (s); LC-MS (ESI) m / z: 447.2[M+H]+.
[0173] Example 27: Preparation of (2-((1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide
[0174]
[0175] Example 27 was obtained by referring to the synthesis steps of Example 10. 1 H NMR (400MHz, DMSO-d6) δ8.88-8.75(m,1H),7.68-7.39(m,2H),7.32(d,J=2.4Hz,1H),7.17-7.07(m,1H),6.98-6.91(m,1H),6.86(d,J=3.6 Hz,1H),6.71(d,J=8.8Hz,1H),6.40(d,J=3.6Hz,1H),3.39(d,J=5.2Hz,2H),3.21-3.10(m,2H),2.69-2.58(m,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.26 (s); LC-MS (ESI) m / z: 433.2[M+H]+.
[0176] Example 28: Preparation of 7-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one
[0177]
[0178] Example 28 was obtained by referring to the synthesis steps of Example 9. 1 H NMR (400MHz, DMSO) δ11.96(s,1H),11.77(s,1H),10.24(s,1H),9.21(s,1H),9.11(s,1H),8.04(s,1H),7.72(d,J=8.3Hz,1H),7.62(dd,J=14.2,7. 6Hz,1H),7.55(t,J=7.8Hz,1H),7.13(s,1H),6.47(s,1H),6.76(d,J=8.4 Hz,1H),2.82(t,J=7.6Hz,2H),2.48-2.39(m,2H),1.79(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.36 (s); LC-MS (ESI) m / z: 447.2[M+H]+.
[0179] Example 29: Preparation of (2-(((1,2,3,4-tetrahydroquinolin-7-yl)amino)7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide
[0180]
[0181] Example 29 was obtained by referring to the synthesis steps of Example 10. 1 H NMR (400MHz, DMSO) δ8.88-8.75(m,1H),7.68-7.39(m,2H),7.32(d,J=2.4Hz,1H),7.17-7.07(m,1H),6.98-6.91(m,1H),6.86(d,J=3. 6Hz,1H),6.71(d,J=8.8Hz,1H),6.40(d,J=3.6Hz,1H),3.39(s,2H),3.21-3.12(m,2H),2.62(t,J=6.0Hz,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.13 (s); LC-MS (ESI) m / z: 433.2[M+H]+.
[0182] Example 30: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one
[0183]
[0184] Refer to the synthesis steps 1 and 2 of Example 20 to obtain (2-((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide, and then refer to the synthesis steps 1 of Example 8 and the synthesis steps of Example 22 to obtain the target product. 1 H NMR(400MHz,MeOD–d4)δ8.47-8.40(m,1H),7.79-7.64(m,4H),7.43(t,J=7.0Hz,1H),7.06(d,J=8.5Hz,1H),6.71-6.63(m,1 H),4.75(s,1H),4.63(s,1H),4.38(s,1H),4.34(s,1H),3.99(s,1H),3.81(d,J=6.0Hz,1H),3.36(s,1H),3.24–3.07(m,2H), 1.90 (d, J = 13.6 Hz, 6H); 31 P NMR (162MHz, MeOD–d4) δ 49.01-47.51 (m); LC-MS(ESI)m / z: 492.1[M+H] + .
[0185] Example 31: Preparation of 2-(2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0186]
[0187] Example 31 was obtained by referring to the synthetic steps of Example 20. 1H NMR (400MHz, MeOD) δ8.38-8.31(m,1H),7.72-7.52(m,2H),7.48(d,J=2.8Hz,1H),7.32(t,J=6.8 Hz,1H),7.02(d,J=2.4Hz,1H),6.87-6.81(m,1H),6.78(d,J=8.8Hz,1H),6.33(d,J=2.8Hz,1H), 4.24 (s, 4H), 1.87 (d, J=13.6Hz, 6H); 31 P NMR (162 MHz, MeOD) δ 48.29 (s); LC-MS (ESI) m / z: 436.0[M+H] + .
[0188] Example 32: Preparation of (2-((5-chloro-2-((6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0189]
[0190] Using tert-butyl(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propyl)carbamate as raw material, Example 15 was obtained by referring to the synthesis steps of Example 14, wherein in Step 3, Cs2CO3 was replaced by KCO3, and the other steps remained unchanged. 1 HNMR (400MHz, MeOD): δ8.54(s,1H),8.27(s,1H),7.84-7.54(m,2H),7.37(t,J=7.2Hz,1H),3.50(s,1H), 3.08-3.04(m,3H),2.87-2.51(m,3H),2.30(d,J=10.8Hz,1H),2.05-1.61(m,9H),1.06(t,J=7.2Hz,3H); 31 P NMR (162MHz, MeOD) δ45.94 (s); LC-MS (ESI) m / z: 491.0 [M+H]+.
[0191] Example 33: Preparation of 1-(2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone
[0192]
[0193] To a solution of 1-(2-amino-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethane-1-one (400 mg, 1.63 mmol) in toluene (20 mL) were added (2-(2,5-dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (515 mg, 1.63 mmol), Pd2dba3 (74 mg, 0.08 mmol), BINAP (105 mg, 0.16 mmol), and Cs2CO3 (1.06 g, 3.26 mmol) under argon protection. The mixture was replaced with nitrogen and heated to 100°C. The mixture was stirred for 13 h. After the reaction mixture was cooled to room temperature, it was filtered through celite and concentrated under reduced pressure. The residue was purified and separated by silica gel column chromatography (PE / EA=1 / 0–1 / 1) to obtain the target compound 33 (yield: 5.2%, 44.2 mg, yellow solid). 1 H NMR (400MHz, DMSO) δ11.38(s,1H),9.87(d,J=3.2Hz,1H),8.84(s,1H),8.25(s,1H),8.00(d,J=8.8Hz,1H),7.62 -7.56(m,3H),7.18(t,J=7.2Hz,1H),4.74(d,J=10.0Hz,2H),4.05-3.75(m,2H),2. 93 (dd, J = 12.4, 6.0 Hz, 2H), 1.79 (d, J = 13.6 Hz, 6H); LC-MS (ESI) m / z: 525.2 [M+H]+.
[0194] Example 34: Preparation of (2-(5-chloro-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)pyrimidin-4-yl)amine)phenyldimethylphosphine oxide
[0195]
[0196] 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethane-1-one (57 mg, 0.108 mmol) was dissolved in THF (1 mL) and MeOH (2 mL) at room temperature, K2CO3 (45 mg, 0.325 mmol) was added, and then stirred at 60°C for 3 h. The reaction was completed as monitored by TLC (DCM / MeOH=15 / 1). After the reaction mixture was cooled to room temperature, water (20 mL) was added to quench and dilute it, and it was extracted with DCM (20 mL×3). The organic phase was washed with saturated aqueous NaCl solution (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified and separated by Prep-HPLC to obtain the target compound 34 (yield: 58.8%, 27.4 mg, white solid). 1 H NMR (400MHz, DMSO) δ11.41(s,1H),9.96(s,1H),9.11(s,2H),8.86(dd,J=8.4,4.0Hz,1H),8.26(s,1H),8.02(d,J=8.8Hz,1H),7.69-7.45(m, 3H), 7.19 (t, J = 7.2Hz, 1H), 4.26 (s, 2H), 3.50 (t, J = 6.4Hz, 2H), 3.00 (t, J = 6.0Hz, 2H), 1.79 (d, J = 13.6Hz, 6H); LC-MS (ESI) m / z: 429.0 [M+H]+.
[0197] Example 35: Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0198]
[0199] Example 35 was obtained by referring to the synthesis steps of Example 1. 1 H NMR (400MHz, CDCl3) δ10.89(s,1H),8.64-8.61(m,1H),7.49(t,J=8.0Hz,1H),7.31–7.23(m,2H),7.19(d,J=2.4Hz,1H),7.14–7.07(m,1H),6.92 -6.90(m,2H),6.80(d,J=8.8Hz,1H),4.26(d,J=2.4Hz, 4H), 1.83 (d,J=13.2Hz, 6H); 31P NMR (162 MHz, MeOD) δ 44.02 (s); LC-MS (ESI) m / z: 431.1[M+H] + .
[0200] Example 36: Preparation of 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one
[0201]
[0202] Using Example 34 as raw material, refer to Step 1 of Example 7 to obtain the target compound 36. 1 H NMR (400MHz, DMSO) δ11.37(s,1H),9.79(s,1H),8.86(d,J=14.8Hz,1H),8.2 4(s,1H),7.95(d,J=7.2Hz,1H),7.53(dd,J=14.8,8.4Hz,3H),7.18(s,1H),4 .60(s,2H),4.54(s,1H),4.25–4.14(m,2H),3.79(s,1H),3.68(s,1H),2.88 (s, 1H), 2.80 (s, 1H), 1.79 (d, J = 13.6Hz, 6H); LC-MS (ESI) m / z: 487.2[M+H]+.
[0203] Example 37: Preparation of (2-((5-chloro-2-((6-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
[0204]
[0205] The target compound 37 was synthesized by referring to step 1 of Example 8. 1 H NMR (400MHz, MeOD): δ8.26(s,1H),8.05(s,1H),7.84–7.54(m,2H),7.37(t,J=7.2Hz,1H ),2.65-3.69(m,8H),2.82(s,3H),1.72(d,J=13.6Hz,6H); LC-MS(ESI)m / z:463.2[M+H] + .
[0206] Example 38: Preparation of (2-((-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-4H-thiazolo[4,5-d]azepine-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone
[0207]
[0208] Using Example 37 as the raw material, the deprotection was carried out according to Example 34, and then according to Step 1 of Example 7 to obtain the target compound 38. 1 H NMR (400MHz, MeOD): δ8.52(s,1H),8.09(s,1H),7.72–7.43(m,2H),7.35(t,J=7.2Hz,1H ),2.65-3.65(m,16H),2.52(m,1H),1.78(d,J=13.6Hz,6H); LC-MS(ESI)m / z:561.2[M+H] + .
[0209] Example 39: Preparation of 2-(4-(5-chloro-4-(2-dimethylphosphonylphenyl)aminopyrimidin-2-ylamino)-3-methylpyrazole-2-methylpropionitrile
[0210]
[0211] Refer to step 1 of Example 8 to obtain the target Example 39. 1 H NMR (400 MHz, DMSO)δ
[0212] 11.24-11.11(m,1H),8.74-8.64(m,1H),8.51-8.31(m,1H),8.16-8.08(m,1H),8.01-7.87(m,1H),7.62-7.52(m,1H), 7.49-7.32(m,1H),7.17-7.05(m,1H),2.13(s,3H),1.89(s,6H),1.78(d,J=13.6Hz,6H); LC-MS(ESI)m / z:444.1[M+H] + .
[0213] Effect experiment:
[0214] Experimental Example 1: In vitro evaluation of the inhibitory activity of the test compound on LRRK2 and LRRK2(G2019S) kinases
[0215] Experimental purpose: Use Promega's ADP-Glo Kinase Assay to evaluate the inhibitory activity of the test compound on LRRK2 and LRRK2 (G2019S) kinases and calculate the IC50 value.
[0216] Materials and reagents: ADP-Glo Kinase Assay (Promega, V9102); LRRK2 (Invitrogen, PV4873); LRRK2 (G2019S) (Carna, 09-146); LRRK2 tide (SignalChem, L10-58); ATP (Promega, V910B); DTT (SignalChem, D86-09B); DMSO (Sigma, D8418); GNE-0877 (MCE, HY-13488)
[0217] Experimental steps:
[0218] 1. Preparation of 1x kinase buffer: 1x kinase reaction buffer and 4x distilled water, 1.5mM DTT.
[0219] 2. Dissolve the positive control and the test compound in DMSO and prepare 10mM as a stock solution. Dilute the above stock solutions to 100uM with DMSO, and then perform 3-fold gradient dilutions in sequence to obtain 10 concentration gradients, with 100μM as the starting concentration. Negative control for LRRK2 kinase and LRRK2(G2019S) kinase: 100% DMSO. Use Echo 550 to transfer the compound dilutions to each well of the assay plate (784075, Greiner) so that the concentrations of the test compounds and the positive control GNE-0877 in the final reaction solutions of the LRRK2 and LRRK2 (G2019S) kinase tests are 1000nM, 333.33nM, 111.11nM, 37.037nM, 12.345nM, 4.1152nM, 1.3717nM, 0.4572nM, 0.1524nM, and 0.0508nM, respectively.
[0220] 3. Seal the analysis plate and centrifuge the composite plate at 1000 g for 1 min.
[0221] 4. Prepare 2× enzyme in 1× kinase buffer: Prepare 2× LRRK2 and 2×LRRK2(G2019S) kinase solutions in 1× kinase reaction buffer.
[0222] 5. Add 2.5 μl of 2x enzyme to a 384-well assay plate (784075, Greiner), centrifuge the plate at 1000 g for 30 s, and incubate at room temperature for 10 min.
[0223] 6. Prepare 2× substrate and ATP mix in 1× kinase buffer. Centrifuge the plate at 1000 g for 30 seconds by adding 2.5 μl of 2× substrate and ATP mix. Seal the assay plate and incubate at room temperature for 2 hours.
[0224] 7. Add 4 μl ADP-Glo reagent and incubate at room temperature for 40 minutes.
[0225] 8. Add 8 μl of kinase assay reagent and incubate at room temperature for 40 minutes.
[0226] 9. Read the luminescent signal on the Envision 2104 plate reader.
[0227] Calculation of inhibition percentage: inhibition rate (%) = 100-(Signalcmpd-SignalAve PC) / (SignalAveVC-SignalAve PC)×100.
[0228] Calculate IC50 and fit compound dose-effect curve: Use GraphPad 8.0 and the following nonlinear fitting formula to obtain the IC50 of the compound:
[0229] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))
[0230] Wherein, X: log value of compound concentration; Y: inhibition percentage of compound.
[0231] Quality control: Z factor>0.5; S / B>2. Positive control IC50 is within 3 to 5 times of historical data.
[0232] Table 1: LRRK2 and LRRK2(G2019S) kinase inhibitory activity test results
[0233]
[0234]
[0235] Experimental Example 2
[0236] Experimental purpose: To evaluate the inhibitory ability of the test compound on the phosphorylation level of LRRK2 protein in Hek293 LRRK2 cells using AlphaLISA detection method.
[0237] Materials and reagents: Hek293-LRRK2 WT cells (stable cell line, Pharmaron), DMEM (Gibco), AlphaLISA SureFire Ultra p-LRRK2 (Ser935), Assay (PerkinElmer, ALSU-PLRRK2-A500), G418 (Gibco, 10131027), Penicillin-Streptomycin (Gibco, 15140-122), FBS (Gibco, 10099-141).
[0238] Experimental steps:
[0239] All cells were cultured according to ATCC recommendations. Cells were analyzed for index. Cell culture medium: DMEM medium, 10% FBS and 1*PS, 500ug / ml G418. Culture conditions: 37°C, air, 95%; carbon dioxide (CO2), 5%. Cells with viability greater than 90% were collected from the flasks, and 25μl of Hek293-LRRK2 cell suspension was distributed into 384-well cell culture plates at a rate of 80,000 cells / well. The cells were incubated overnight at 37°C, 5% CO2 incubator.
[0240] The test compound was dissolved in DMSO to prepare 10mM as a stock solution. All compounds were diluted 2-fold with DMSO solution, and then 3-fold gradient dilutions were performed in sequence, 9 concentration gradients, and DMSO samples without compounds, with a total of 10 stock concentrations of the test compound. 25nl of the serial dilutions were added to a 384-well cell plate by Echo and cultured in a 37°C, 5% CO2 incubator for 2 hours.
[0241] Detection: Cell lysates were prepared and assayed according to the manufacturer's protocol and read by Envision AlphaScreen.
[0242] Calculate the inhibition percentage: Inhibition rate (%) = 100-(Signalcmpd-SignalAve PC) / (SignalAveVC-SignalAve PC)×100
[0243] SignalAve PC: Average of AlphaScreen reads across the positive control wells
[0244] SignalAve VC: Average of AlphaScreen reads across the blank wells
[0245] Calculation of IC50 and fitting of compound dose-effect curves: GraphPad 6.0 was used to obtain the IC50 of the compound using the following nonlinear fitting formula.
[0246] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))
[0247] Wherein, X: log value of compound concentration; Y: inhibition percentage of compound.
[0248] Data review: Data were exported from the reader and analyzed manually. Luminescence values were converted to % inhibition. All IC50s were first calculated using % inhibition by Prism Graphpad 5.0. IC50s were then recalculated using luminescence values to check the accuracy of the analysis results.
[0249] Experimental results: The test results of LRRK2 protein phosphorylation inhibition activity in Hek293 LRRK2 cells are shown in Table 2.
[0250] Experimental Example 3
[0251] Experimental purpose: To evaluate the inhibitory ability of the test compound on the phosphorylation level of LRRK2 protein substrate Rab10 in LRRK2 R1441G mouse embryonic fibroblasts by Western Blot method.
[0252] 1. Cell line: (LRRK2R1441G mouse embryonic fibroblasts, stable cell line)
[0253] 2. The test compound was dissolved in DMSO and prepared to 10 mM as a stock solution. The stock solution was diluted 10-fold or 100-fold with DMSO solution, and then 2-fold or 10-fold gradient dilution was performed in sequence, 4 concentration gradients, and a DMSO sample without compound, for a total of 5 stock solution concentrations of the test compound.
[0254] 3. LRRK2 R1441G mouse embryonic fibroblasts were cultured using DMEM medium at 37°C and 5% (v / v) CO2, and the experiment was performed during the exponential growth phase.
[0255] 4. Gently discard the culture supernatant and wash the cells twice with PBS. Digest the cells with trypsin digestion solution, terminate the digestion with complete culture medium, collect the cells and count them. Plant the cells in a 96-well cell culture plate, 5×10 cells per well. 4 cells, 100 μL culture medium. The cell culture plate was cultured in a 37°C, 5% (v / v) CO2 incubator for 2 hours.
[0256] 5. Add 100 nL of the prepared compound working solution to each well of cells. The final concentration of the test compound is: 100, 10, 1, 0.1 nM or 1000, 500, 100, 10 nM.
[0257] 6. Incubate the cell culture plate in a 37°C, 5% CO2 incubator for 1 hour.
[0258] 7. Protein extraction and sample preparation: Discard the culture medium in the cell culture plate, add 45ul of cell lysis working solution to each well, and incubate on ice for 30 minutes. Use 4x sample preparation working solution for sample preparation, heat at 70℃ for 10min. Store the remaining protein sample at -80℃.
[0259] 8. Western Blot: In the precast gel, load 1-10ug per well, and perform electrophoresis at a constant voltage of 120V for about 60min. Use PVDF membrane for transfer, constant current 300mA, 1 hour. After transfer, block with blocking solution at room temperature for 1 hour. Incubate with primary antibody working solution at 4℃ overnight. Wash the membrane with 1×TBST buffer for 3×10min. Incubate with secondary antibody working solution at room temperature for 1 hour. Wash the membrane with 1×TBST buffer for 3×10min, and expose and develop with color developing solution.
[0260] 9. Data Analysis
[0261] ImagJ software was used to calculate the gray value of each band for semi-quantitative analysis. ImagJ software was used to calculate the gray value of each band of p-Rab10 and Actin, and the sample with 0 nM compound added was set as p-Rab10 / Actin%=100%, and the relative value of Rab10 / Actin% at other treatment concentrations was calculated.
[0262] GraphPad 8.0 was used to obtain the IC50 of the compounds using a nonlinear fitting formula.
[0263] Fitting formula: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC50-X)*HillSlope))
[0264] Wherein, X: log value of compound concentration; Y: inhibition percentage of compound.
[0265] Experimental results: The test results of the compounds inhibiting the p-Rab10 activity in LRRK2 R1441G mouse embryonic fibroblasts are shown in Table 2.
[0266] Table 2: The test effects of the compounds on inhibiting LRRK2 protein phosphorylation in Hek293 LRRK2 cells and inhibiting p-Rab10 activity in LRRK2 R1441G mouse embryonic fibroblasts.
[0267]
[0268] Note: “-” means not tested
[0269] The experimental results are shown in Tables 1 and 2, which confirm that the example compounds of the present invention effectively inhibit LRRK2, LRRK2 (G2019S) and Rab10 kinases. Therefore, the example compounds of the present invention can be effectively used in pharmaceutical compositions for treating and preventing diseases associated with LRRK2, LRRK2 (G2019S) and Rab10 kinases.
[0270] Experimental Example 4: In vitro evaluation of the inhibitory activity of the test compound against EGFR T790M / C797S / L858R kinase
[0271] Experimental purpose: To evaluate the inhibitory activity of the test compound on EGFR T790M / C797S / L858R kinase using Cisbio's HTRF KinEASE-TK kit detection method and calculate the IC50 value.
[0272] Materials and reagents: HTRF KinEASE-TK kit (Cisbio); EGFR T790M / C797S / L858R (signalchem); ATP (Promega, V910B); DTT (Invitrogen); DMSO (Sigma)
[0273] Experimental steps:
[0274] 1. Dissolve the positive control and the test compound in DMSO and prepare 10mM as the stock solution. Dilute the above stock solutions to 100μM with DMSO, and then perform 3-fold gradient dilutions in sequence to obtain 10 concentration gradients, of which 100μM is the starting concentration. Negative control: 100% DMSO. Transfer the diluted working solution of the test compound to each well of the Echo 550 reaction plate (784075, Greiner). The final concentrations of the test compound and the positive control in the EGFR T790M / C797S / L858R kinase test reaction solution are 1000nM, 250nM, 62.5nM, 15.62nM, 3.9nM, 0.97nM, 0.24nM, and 0.06nM, respectively.
[0275] 2. Seal the reaction plate with sealing film and centrifuge at 1000g for 1 minute.
[0276] 3. Prepare 2× kinase using 1× enzyme reaction buffer
[0277] 4. Add 5 μL of the above-prepared kinase solution to the reaction plate, seal the reaction plate with a sealing film, centrifuge at 1000 g for 30 seconds, and leave at room temperature for 10 minutes.
[0278] 5. Prepare 2x kinase substrate and ATP mixture using 1x enzyme reaction buffer.
[0279] 6. Add 5 μL of the above solution to the reaction plate, centrifuge at 1000 g for 30 seconds, and start the reaction for 40 minutes.
[0280] 7. Add 5ul 4×Sa-XL 665-prepared HTRF detection buffer and 5uL TK-antibody-Cryptate to each reaction well, centrifuge at 1000g for 30 seconds, and incubate at room temperature for 1 hour.
[0281] 8. Read the fluorescence signal values at 615 nm (Cryptate) and 665 nm (XL665) on an Envision 2104 plate reader.
[0282] Calculation of inhibition percentage:
[0283] Inhibition rate (%)=100-(Ratiocmpd-RatioAve PC) / (RatioAve VC-RatioAve PC)×100.
[0284] Ration is the ratio of 665nM / 615nM readings for each test well
[0285] RatioAve PC: Average Ratio value of the entire positive control well
[0286] RatioAve_VC: Average Ratio value of the entire negative control well
[0287] Calculate IC50 and fit compound dose-effect curve: Use GraphPad 6.0 and the following nonlinear fitting formula to obtain the IC50 of the compound:
[0288] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))
[0289] Wherein, X: log value of compound concentration; Y: inhibition percentage of compound.
[0290] Quality control: Z factor>0.5; S / B>2, positive control IC50 is within 3 to 5 times the historical data.
[0291] Experimental results: The results of the EGFR T790M / C797S / L858R kinase inhibition activity test are shown in Table 3.
[0292] Experimental Example 5: In vitro evaluation of the inhibitory activity of the test compound on Ba / F3-FL EGFR Del19 / T790M / C797S cells
[0293] use The detection method evaluates the ability of the test compound to inhibit the activity of Ba / F3-FL EGFR Del19 / T790M / C797S cells.
[0294] Materials and Reagents: (Promega, G7573); RPMI-1640 (VivaCell, C3010-0500); Fetal bovine serum (VivaCell; C04001-500); Ba / F3-FL EGFR Del19 / T790M / C797S (Precedo, RPMI-1640+10%FBS+1%P / S)
[0295] Experiment and steps:
[0296] Preparation of working stock solution of test compound: The test compound is dissolved in DMSO to prepare 10mM as stock solution, and 2μL of 10mM stock solution is added to 98μL growth medium for dilution to obtain 20uM. Cell seeding: Spin down the suspended cells and resuspend them in growth medium, and then count them with a cell counter. Dilute the cell suspension in growth medium to the desired density and place 95μL of the cell suspension in a 96-well plate.
[0297] Inhibition assay: Add 5 μL of 20 uM compound to a 96-well plate according to the plate map. Final DMSO concentration in each well is 0.1%. Incubate at 37°C, 5% CO2 for 72 hours.
[0298] Detection: Before detection, equilibrate the assay plate to room temperature and add 50 μL CellTiter The mixture was shaken on an orbital shaker for 2 minutes to induce cell lysis, incubated at room temperature for 10 minutes to stabilize the luminescent signal, and the fluorescence value was recorded on Paradigm.
[0299] Data analysis: Calculate the inhibition percentage according to the following formula:
[0300] Inhibition rate (%) = 100-(RLU compound-RLU blank) / ((RLU control-RLU blank)×100
[0301] Calculate IC50 and fit compound dose-effect curve
[0302] The IC50 of the compound was obtained using the following nonlinear fitting formula using GraphPad 7.0:
[0303] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))
[0304] Experimental results: The inhibitory activity of Ba / F3-FL EGFR Del19 / T790M / C797S cells is shown in Table 3.
[0305] Table 3
[0306]
[0307]
[0308] Note: “-” means not tested
[0309] The experimental results are shown in Table 3, which confirm that the example compounds of the present invention effectively inhibit the activities of EGFR T790M / C797S / L858R and EGFR Del19 / T790M / C797S. Therefore, the example compounds of the present invention can be effectively used in pharmaceutical compositions for treating and preventing diseases associated with GFR T790M / C797S / L858R and EGFR Del19 / T790M / C797S.
[0310] Experimental Example 6 In vivo efficacy experiment
[0311] Experimental purpose: To evaluate the pharmacodynamics of the compounds on LRRK2 levels in CD-1 mice and provide a reference for clinical research.
[0312] Experimental materials: CD-1 mice (6-8 weeks old, male, 25.6-29.5 g); experimental animal provider: Beijing Sibeifu Biotechnology Co., Ltd.
[0313] Experimental process:
[0314] 1. Animal feeding, animal grouping and handling
[0315] 1.1 Quarantine
[0316] The quarantine period was 7 days, routine health examinations were completed by a veterinarian, and animals showing abnormal performance were culled before the experiment.
[0317] 1.2 Animal housing conditions
[0318] The experimental animals were kept in a laminar flow clean room with SPF level constant temperature and humidity, with 3 mice in one cage. The temperature of the room was 22±3℃, the humidity was 40-80%, and the light was alternated between light and dark for 12 hours. The cages were made of polycarbonate. The soft corn cob was sterilized and cleaned by high pressure and changed twice a week. The drinking water was sterilized by high pressure and the food was irradiated by cobalt 60 rays. The animals could freely take sterile food and drinking water.
[0319] 1.3 Animal number
[0320] Each cage has a cage label indicating the number of animals, sex, strain, receipt time, group, and start time of the experiment. Each animal is marked with an individual animal number at the tail.
[0321] 1.4 Animal grouping and treatment
[0322] On the day of administration, the animals were randomly divided into 6 groups according to their body weight, with 3 animals in each group. The specific grouping and administration schedule are shown in Table 4.
[0323] Table 4 Animal grouping and drug administration
[0324]
[0325] Note: Solvent (ethanol:0.5% methylcellulose (1:19)).
[0326] 2. Medication and Blood and Tissue Collection
[0327] The vehicle or the test compound was administered sequentially. Five hours after administration, the mice were killed by carbon dioxide anesthesia, and blood was collected by cardiac puncture in EP tubes containing EDTA-K2. The blood samples were immediately centrifuged at 4°C, 2000g for 5 min, the supernatant was collected and transferred to a new EP tube, and the plasma was stored in a -80°C refrigerator for Western blot analysis (LRRK2, LRRK2-pS935).
[0328] After blood collection, brains of all animals were collected by dissection, frozen on dry ice, and stored in a -80°C refrigerator for Western blot analysis (LRRK2, LRRK2-pS935).
[0329] 3. Experimental methods and steps
[0330] 3.1 Buffer preparation:
[0331] 3.1.1RIPA lysis buffer:
[0332] 50mL RIPA Lysis Buffer contains the following components:
[0333] complete ultra TabletsMini.EDTA-free,easypack and phosphatase inhibitor cocktail.
[0334] Keep the prepared lysis buffer on ice until use;
[0335] 3.1 2 Transfer buffer:
[0336] Add and dissolve 100 mL of 10× transfer buffer and 200 mL of methanol in 700 mL of ddH2O.
[0337] 3.1.3MOPS electrophoresis buffer:
[0338] 100 mL of 20×MOPS buffer was diluted to 2000 mL with ddH2O.
[0339] 3.1.4TBST buffer:
[0340] Dilute 100 mL of 10× TBST buffer to 1000 mL with ddH2O.
[0341] 3.1.5 Blocking buffer:
[0342] 2.5 g skim milk was dissolved in 50 mL 1× TBST buffer and stored at 4°C.
[0343] 3.1.6 Primary antibody solution:
[0344] Dilute the target primary antibody at a ratio of 1:1000 with blocking buffer, and dilute the internal control antibody at a ratio of 1:5000 with blocking buffer.
[0345] 3.1.7 Secondary antibody solution:
[0346] The secondary antibody was diluted in antibody solution at a ratio of 1:5000.
[0347] 3.2. Protein lysate preparation
[0348] 3.2.1 Resuspend the sample (about 30 mg) in 300 μL of lysis buffer and homogenize the sample on TissueLyserⅡ with grinding beads at 30 Hz for 3 minutes in a cold room. Place the test tube on ice and mix the sample at 4°C for 30 minutes.
[0349] 3.2.2 Centrifuge at 12000g for 15 minutes at 4°C to pellet any remaining undissolved tissue. Collect the supernatant into clean Eppendorf centrifuge tubes, aliquot the supernatant into small volumes, and store at -80°C.
[0350] 3.2.3 Determine the protein concentration of 3 μg / μl using BCA assay.
[0351] 3.3 Immunoblotting
[0352] 3.3.1 Extract 30 μg of protein from each sample and run electrophoresis at a constant voltage of 120 V until the blue marker reaches the end of the gel.
[0353] 3.3.2 Transfer to NC membrane using Transblot (0.3A, 1.5h).
[0354] 3.3.3 After transfer, block the membrane with blocking buffer for 1 hour at room temperature.
[0355] 3.3.4 Incubate the membrane with the primary antibody at the recommended dilution using Antibody Dilution Buffer at 4°C overnight.
[0356] 3.3.5 Wash the membrane with 1× TBST for 6×5 min and incubate the membrane with secondary antibody for 1 hour at room temperature.
[0357] 3.3.6 Wash the membrane with 1×TBST for 6×5 min and detect with Odyssey CLx.
[0358] 3.3.7 Use Image studio to analyze the ratio of the target band.
[0359] 4. Experimental results:
[0360] 4.1 Western Blot results of brain tissue Figure 4 .
[0361] 4.2 Plasma Western Blot Results Figure 5 .
[0362] Conclusion: The compounds of the present invention have a significant inhibitory effect on the phosphorylation level of LRRK2 in mouse brain tissue.
[0363] Experimental Example 7 In vivo efficacy in tumor models
[0364] Objective: To evaluate the efficacy of the compound in a human ovarian cancer model
[0365] 1 Female BALB / c nude mice, 5-6 weeks old.
[0366] 2Day 0 All animals were subcutaneously inoculated with OVCAR8 cells; when the average tumor volume reached 150-200mm 3 The medication was grouped as shown in Table 5.
[0367] Table 5
[0368]
[0369] The animals were observed at the cage side once a day and observed in detail each time the drug was administered. After the start of drug administration, the body weight and tumor volume were measured twice a week. On the day when the experiment ended, the animals were photographed by group, the weight of the exfoliated tumor was weighed, and the exfoliated tumor was photographed as a whole by group.
[0370] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A heteroaryl derivative, characterized in that: The general structural formula I is as follows: in: X and Y are independently selected from halogen or hydrogen, or together with the nitrogen-containing six-membered ring to which they are connected, form a nitrogen-containing five-membered ring; R1 is a 5-6 membered aromatic group or a heteroaromatic group containing N and S, the aromatic ring and the heteroaromatic group are substituted by 0-2 substituents, the substituents are C1-3 alkyl groups or alkyl groups substituted by cyano groups; or two substituents can be connected to form a ring, the ring is a 5-7 membered cycloalkyl group, a lactam cycloalkyl group or a heterocycloalkyl group or heteroaromatic group containing N and O, the heterocycloalkyl group or heteroaromatic group is substituted by 0-3 substituents, the substituents are C1-3 alkyl groups, keto groups, trifluoroacetyl groups, hydroxyacetyl groups, alkylamino groups, heterocycloalkanoyl groups.
2. The heteroaryl derivative according to claim 1, characterized in that: Y is selected from Cl, X is selected from H, or the nitrogen-containing six-membered ring they are connected to together form 3. The heteroaryl derivative according to claim 1, characterized in that: R1 is One of them.
4. The heteroaryl derivative according to claim 1, characterized in that: The compound of general formula I is one of the following: Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-(2-(1-methyl-1H-pyrazol-4-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; (2-(2-(1-methyl-1H-pyrazol-3-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; (2-(2-((1H-indazol-6-yl)amino)-7H-purin-6-amino)phenyl)dimethylphosphine oxide; (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone; 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 6-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; (2-((2-(1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 7-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; (2-((2-(1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 2-(4-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile; (2-((6-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((6-(((5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridin-2-yl)amino)-1H-pyrazol[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((6-((6-propylamino)-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)yl)-2,2,2-trifluoroethanone; (2-((6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(3-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; (2-((2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-2,2,2-trifluoroethanone; (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 2-(4-((4-)((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile; 6-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; (2-(((1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide; 7-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(H)-one; (2-(((1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; 2-(2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((5-chloro-2-((6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone; (2-(5-chloro-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)pyrimidin-4-yl)amine)phenyldimethylphosphine oxide; (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; (2-((5-chloro-2-((6-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-4H-thiazolo[4,5-d]azepin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone; 2-(4-(5-Chloro-4-(2-dimethylphosphonophenyl)aminopyrimidin-2-ylamino)-3-methylpyrazole-2-methylpropionitrile.
5. Use of the heteroaryl derivative according to any one of claims 1 to 3 in the preparation of LRRK2 kinase or abnormal LRRK2 mutant kinase and / or EGFR mutant kinase inhibitor drugs.
6. A drug for inhibitor of LRRK2 kinase or / and abnormal LRRK2 mutant kinase or / and EGFR mutant kinase, characterized in that: A heteroaryl derivative comprising any one of claims 1 to 3 or an enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient or excipient thereof.
7. A pharmaceutical composition, characterized in that: The invention comprises a heteroaryl derivative according to any one of claims 1 to 3 or an enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient thereof.
8. A pharmaceutical composition, characterized in that: The pharmaceutical composition is a combination of the drug described in claim 7 and other drugs, and the other drugs are drugs for treating breast cancer.
9. The LRRK2 kinase or / and abnormal LRRK2 mutant kinase or / and EGFR mutant kinase inhibitor drug according to claim 6 or the pharmaceutical composition according to claim 7 or 8, characterized in that: The dosage form is tablet, capsule, solution, suspension, granule or injection, and is administered orally or parenterally.
10. Use of the heteroaryl derivative according to any one of claims 1 to 3, or the LRRK2 kinase or abnormal LRRK2 mutant kinase or / and EGFR mutant kinase inhibitor according to claim 6, or the pharmaceutical composition according to claim 7 or 8 in the preparation of drugs for preventing and / or treating central nervous system diseases, cancer and immune diseases.
11. The use according to claim 10, characterized in that: The central nervous system (CNS) diseases include Alzheimer's disease, L-dopa-induced dyskinesia, Parkinson's disease, ischemic stroke, traumatic brain injury or spinal cord injury; the cancers include kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myeloid leukemia, multiple myeloma, brain cancer, etc.; the immune diseases include leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis or ankylosing spondylitis.
